SK Biopharmaceuticals has secured an exclusive global license to Biohaven's Kv7 platform drug opakalim, a next-gen treatment for focal epilepsy currently in Phase 2/3 trials with results expected in late 2026. The deal includes $400 million upfront to Biohaven, milestone payments up to $795 million, and tiered royalties on U.S. sales. This partnership leverages SK Biopharmaceuticals' proven epilepsy commercial expertise to bring opakalim to patients worldwide, while Biohaven gains non-dilutive capital and retains long-term revenue potential. The collaboration aims to advance opakalim through FDA approval and global commercialization, offering a novel once-daily oral epilepsy treatment with fewer CNS side effects.
IREN Limited is set to report earnings showing a significant revenue drop from $187.3 million to around $132-142 million year-over-year, with an expected loss per share of approximately -$0.55 compared to last year's profit. The company faces challen...
Real REMAX Group finalized its acquisition of RE/MAX Holdings on August 24, 2026, forming a combined company with over 180,000 agents worldwide. The new entity trades on Nasdaq under the ticker REAX and blends Real's technology platform with RE/MAX's...
Build-A-Bear Workshop reported Q2 earnings per share of $0.70, beating analyst estimates despite a decline from $0.94 last year. However, revenue fell 7.2% year-over-year to $115.29 million, missing expectations and leading to a lowered annual sales ...
Workday reported fiscal Q2 revenues of $2.649 billion, up 12.8% year-over-year, driven by a 13.9% increase in subscription revenues to $2.471 billion. Operating income improved to $313 million, supported by AI adoption which now influences over 25% o...
Autodesk reported a 16% year-over-year revenue increase to $2.05 billion in Q2 fiscal 2027, driven by strong sales across design and manufacturing segments and the recent acquisition of MaintainX. The company highlighted AI integration as a key growt...
